Back to School: How biopharma can reboot drug development. Access exclusive analysis here
ONXX and partner Bayer (FSE:BAYG; BAY) said interim results from a Phase II study in patients with
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury